NeuroPace wins five-year $9.3M grant from NIH
Summary
NeuroPace today announced that it has received a $9.3 million National Institutes of Health grant to study Lennox-Gastaut Syndrome treatment. “LGS is a horrific epilepsy syndrome that develops in very young children and results in daily seizures, frequent seizure emergencies and hospitalizations, and significant developmental delays,” Tracy Dixon-Salazar, executive director of the LGS Foundation, said in a news release. Two other academic sites will create patient-specific maps of brain seizure networks for better insight into how to personalize the treatment for each participant. “We are pleased that the NIH recognizes the promise of responsive neuromodulation to potentially address the current gap in therapeutic options for patients with debilitating seizure disorders such as LGS,” NeuroPace chief medical officer Martha Morrell said. “These recordings obtained directly from the brain in a natural setting will show us what is happening when an LGS seizure starts and spreads.